TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01357889

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide (GSK716155)
Description: subcutaneous injection administered once a week

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: albiglutide (GSK716155)
Description: subcutaneous injection administered once a week
Study: NCT03454204

Intervention type: OTHER
Intervention: Pharmacokinetic
Description: Analysis of blood samples
Study: NCT04402619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: The ten modules cover:~* Psychoeducation about sleep, sleep problems, and associations with alcohol~* How to keep and use a sleep diary~* Sleep hygiene~* Sleep compression~* Cognitive restructuring~* Emotional regulation~* Preparing for the future
Study: NCT00054236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide IV over 2 hours on days -3 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: fludarabine IV over 30 minutes on days -8 to -4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
Study: NCT00857584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adequate mood stabilizer
Description: An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
Study: NCT06489457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide subcutaneous injection once weekly titrated to 1 mg in concordance with Summary of product characteristics (SmPC) (0.25 mg once weekly in the first month, 0.5 mg once weekly in the second month and 1 mg once weekly from the third month onward)
Study: NCT05729269

Intervention type: DIAGNOSTIC_TEST
Intervention: Sarcopenia_CT
Description: measurement of skeletal muscle through abdominal computed tomography
Study: NCT01040845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone/Ethinyl Estradiol
Description: one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
Study: NCT06489457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: Testosterone Undecanoate intramuscular injection 1000 mg once per 10-12 weeks
Study: NCT02774096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon
Study: NCT04642937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with hP1A8
Description: Treatment with hP1A8
Study: NCT02838810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa
Description: peginterferon alfa-2b or peginterferon alfa-2a

Intervention type: DRUG
Group type: OTHER
Intervention: Nucleoside analogues
Description: Nucleoside analogues
Study: NCT02737332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zytiga® (Abiraterone Acetate)
Description: Zytiga® 1,000 mg (4 x 250 mg qd) tablets plus one 5 mg prednisone tablet to be taken bid, spaced approximately 12 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoluMatrix™ (Abiraterone Acetate)
Description: SoluMatrix™ 500 mg (4 x 125 mg qd) tablets plus one 4 mg methylprednisolone tablet bid, spaced approximately 12 hours apart
Study: NCT00475150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03102801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin S
Description: Humulin S used to induce hypoglycaemia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin S
Description: Humulin S used to induce hypoglycaemia
Study: NCT00432302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY 86-5302, ZK 219477)
Description: First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
Study: NCT03512418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPsteps
Description: Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital pill
Description: The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital pill
Description: The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Participants receive once daily Truvada as PrEP to prevent HIV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants receive once daily Truvada as PrEP to prevent HIV.
Study: NCT02177656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing tailored intervention
Description: MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
Study: NCT03261960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4700
Description: Oral bowel preparation
Study: NCT01040845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norethindrone/Ethinyl Estradiol
Description: one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
Study: NCT00912782

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one time per week for 3 weeks
Study: NCT01861665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine- 0.25%
Description: Marcaine 0.25% administered pre-incision.
Study: NCT03261960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium bowel preparation
Description: Oral bowel preparation
Study: NCT01752686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin as adjuvant chemotherapy
Study: NCT00045669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study: NCT01861665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25%.
Description: Marcaine 0.25% administered post-incision.
Study: NCT03121144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Centroid System
Description: Noninvasive positional monitoring device
Study: NCT01040845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6mg tablet every 12 hours on Days 8 to 21
Study: NCT03928041

Intervention type: DEVICE
Group type: OTHER
Intervention: Device: EVOS Lumbar Interbody System (EVOS-HA)
Description: All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
Study: NCT01040845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: 0.6mg tablet every 12 hours on Days 8 to 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Colchicine)
Description: placebo tablet every 12 hours on Days 8 to 21
Study: NCT03121378

Intervention type: OTHER
Intervention: Blood sample 1
Description: Blood taken before prosthesis implantation

Intervention type: OTHER
Intervention: Blood sample 1
Description: Blood taken before prosthesis implantation

Intervention type: OTHER
Intervention: Blood sample 2
Description: Blood taken after prosthesis implantation

Intervention type: OTHER
Intervention: Blood sample 2
Description: Blood taken after prosthesis implantation
Study: NCT02431182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Training Workshop
Description: 1. Presentation of the workshop: Objectives and Methodology~2. Explanation of the different types of memory and its implication in normal life~3. Strategies for gathering and codification of the information~4. Strategies for selection and storage the information~5. Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~6. Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~7. Strategies for recuperation according to the individual profile. Improving self-esteem~8. Strategies for recuperation Social skills.~9. Personal and social skills~10. New contexts and opportunities~11. Evaluation of the workshop
Study: NCT03180112

Intervention type: GENETIC
Intervention: enzyme linked immunosorbent assay and polymerase chain reaction
Description: Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.

Intervention type: GENETIC
Intervention: enzyme linked immunosorbent assay and polymerase chain reaction
Description: Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
Study: NCT04271358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Health Coaching
Description: The Peer Coaching group will receive 6 months of peer health coaching via a secure telephone and text messaging system.
Study: NCT01427218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titration of medications
Description: Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Counseling
Description: The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care with Medication Reconciliation
Description: A medication history and assessment of adherence will be completed by the pharmacist.
Study: NCT01761708

Intervention type: PROCEDURE
Intervention: primary ventral hernia repair with mesh
Study: NCT04389905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental education - Motivational Interviewing
Description: Motivational Interviewing - Focusing on oral/dental health
Study: NCT02336815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg was given with each dose of Selinexor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg was given with each dose of Selinexor.
Study: NCT02002507

Intervention type: OTHER
Intervention: comparison of different neurosurgical position
Description: in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)

Intervention type: OTHER
Intervention: comparison of different neurosurgical position
Description: in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
Study: NCT01333722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen Extended Release
Study: NCT01040845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Colchicine)
Description: placebo tablet every 12 hours on Days 8 to 21
Study: NCT00086736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study: NCT01333722

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT00003846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT00042289

Intervention type: DRUG
Intervention: efavirenz
Description: efavirenz 600 mg q.d.

Intervention type: DRUG
Intervention: efavirenz
Description: efavirenz 600 mg q.d.
Study: NCT00086736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral eflornithine placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral eflornithine placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral bicalutamide placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral bicalutamide placebo
Study: NCT00649168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
Description: 2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study: NCT00003846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study: NCT00472862

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Cognitive training for 16 weeks integrated in OPUS psychosocial treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
Study: NCT00003846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02829996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 6.0% / latanoprost 0.005% QD
Description: Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 3.0% / latanoprost 0.005% QD
Description: Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabodenoson 6.0% / latanoprost 0.0025% QD
Description: Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.005% QD
Description: Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost 0.0025% QD
Description: Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
Study: NCT00649168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Description: 2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study: NCT00961116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid (Fibricor™) 105 mg Tablet
Description: 1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor®) 145 mg Tablet
Description: 1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
Study: NCT01459770

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Information Transfer Intervention
Description: A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care for hospital discharge
Description: Patients will receive medication information according to standard practice for discharge of hospitalized patients.
Study: NCT00389441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
Study: NCT03530150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone Oral Product
Description: A pill containing 600 mg of pirfenidone
Study: NCT02309814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eyelid motion sensor device (Hall-probe)
Description: all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
Study: NCT02124941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FDG PET scan
Description: All subjects will undergo \[18F\]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
Study: NCT04120129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS coil
Description: The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.
Study: NCT00198458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitrase
Study: NCT01539213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab (AIN457)
Description: anti-IL-17 antibody
Study: NCT01732107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
Study: NCT03005041

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biotene mouthwash
Description: Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.

Intervention type: OTHER
Group type: OTHER
Intervention: Bottled mineral water
Description: Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
Study: NCT03791268

Intervention type: PROCEDURE
Intervention: Gastric cancer surgery
Description: Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.